People · Operator
Named in public records as an officer, director or promoter · active 2010–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atreca, Inc. | — | Biotechnology | Series D+ | $222.2M | $5.2B | 2011 |
| Nuon Therapeutics Inc | — | Biotechnology | Series A | $29.7M | $361.5M | 2010 |
Tito Serafini at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tito Serafini on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franklin Berger | 1 | 7 |
| Robert More | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| Bob More | 1 | 6 |
| Brian Atwood | 1 | 6 |
| Arlene Morris | 1 | 5 |
| William Robinson | 1 | 5 |
| Lawrence Steinman | 1 | 4 |
| Joshua Funder | 1 | 3 |
| John Simpson | 1 | 3 |
| David Lacey | 1 | 2 |
| Helen Jenkins | 1 | 2 |
| John Orwin | 1 | 2 |
| Michael Kitt | 1 | 2 |
| Josh Funder | 1 | 1 |
| Susan Berland | 1 | 1 |
| Lee Rauch | 1 | 1 |
| Paulette Dillon | 1 | 1 |
| Rodney Pearlman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.